QGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide.
Qiagen N.V. (QGEN) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Revisions (F). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (2.9) | C- (1.9) | B+ (3.6) | B+ (3.8) | F (0.5) | C+ (2.5) |
| 2026-11-07 | B- (2.9) | C- (1.9) | B+ (3.6) | B+ (3.7) | F (0.6) | C+ (2.5) |
| 2026-10-31 | B- (2.9) | C- (2.0) | B+ (3.6) | B (3.4) | F (0.6) | C+ (2.5) |
| 2026-10-24 | B- (2.9) | C- (2.0) | B+ (3.6) | B (3.2) | C+ (2.6) | B- (2.9) |
| 2026-10-17 | B- (3.0) | C- (2.0) | B+ (3.6) | B- (3.1) | A+ (5.0) | B (3.3) |